Human medicines European public assessment report (EPAR): Zimbus Breezhaler, indacaterol,glycopyrronium,mometasone furoate, Asthma, Date of authorisation: 03/07/2020, Revision: 4, Status: Authorised
Zimbus Breezhaler is an asthma medicine for inhalation. It is used for maintenance (regular) treatment in adults whose asthma is not controlled well enough with inhaled long-acting beta-2 agonist together with a high dose of an inhaled corticosteroid. It should be used for patients who have had at least one asthma attack (exacerbations) in the last year.
Zimbus Breezhaler contains the active substances indacaterol, glycopyrronium bromide and mometasone.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
